ROS1-tyrosine kinase inhibitors have shown efficacy against NSCLC with common ROS1 fusion genes, but the impact of rare fusion partners on therapeutic outcomes is not well understood. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.